## CRM: Salesforce, Inc. - XLK: Technology

### Executive Summary

VALUE thesis: PEG 1.24 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($225.10)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Salesforce Inc earnings beat by $0.39, revenue topped estimates**
- Source: Investing.com South Africa | 20251203T231500 | Bullish | Relevance: 100%
- Salesforce Inc (NYSE: CRM) reported Q3 EPS of $3.25, surpassing analyst estimates by $0.39, with revenue reaching $10.3B against an estimated $10.27B. The company issued Q4 2026 EPS guidance of $3.02-$3.04 and revenue guidance of $11.13B-$11.23B, both above consensus estimates. Salesforce stock has seen a decline of -4.81% in the last 3 months and -35.11% in the last 12 months, despite strong financial health according to InvestingPro.

**2. Salesforce Inc earnings beat by $0.39, revenue topped estimates**
- Source: Investing.com UK | 20251203T211400 | Bullish | Relevance: 100%
- Salesforce Inc (NYSE: CRM) reported Q3 EPS of $3.25, exceeding analyst estimates of $2.86, and revenue of $10.3 billion, topping the consensus of $10.27 billion. The company also provided Q4 2026 guidance, forecasting EPS between $3.02 and $3.04 and revenue between $11.13 billion and $11.23 billion, both above analyst expectations. Salesforce's stock has seen a decline over the last 3 and 12 months, but its financial health is rated as "great performance" by InvestingPro.

**3. Salesforce (CRM) Stock on December 3, 2025: Earnings Preview, Analyst Targets and AI-Driven Outlook**
- Source: ts2.tech | 20251203T190628 | Somewhat-Bullish | Relevance: 100%
- Salesforce (CRM) is facing a critical earnings report on December 3, 2025, with its stock down almost 30% year-to-date despite analyst targets implying significant upside. Investors are focused on whether Salesforce's AI transformation, particularly with Agentforce and Data Cloud, can drive renewed growth and justify its valuation as it transitions from a high-growth stock to a more value-oriented company with strong profitability. The Q3 FY26 results will be a key indicator of the company's progress on its long-term roadmap towards $60 billion in revenue by FY2030 and a return to double-digit growth.

**4. Salesforceâ€™s AI bets gain momentum, but overall growth remains sluggish**
- Source: SiliconANGLE | 20251203T183900 | Somewhat-Bullish | Relevance: 100%
- Salesforce Inc. reported mixed Q3 financial results with earnings beating estimates but revenue falling slightly short. The company's stock rose in late trading due to positive momentum in its agentic artificial intelligence initiatives, specifically the Agentforce platform, which has achieved $540 million in annual recurring revenue. Despite some promising AI growth drivers, overall revenue growth remains sluggish, and the company's full-year guidance indicates that immediate growth will still be modest, with a significant portion expected from its recent acquisition of Informatica.

**5. Salesforce Inc earnings beat by $0.39, revenue topped estimates**
- Source: Investing.com | 20251203T161400 | Bullish | Relevance: 100%
- Salesforce Inc (NYSE: CRM) reported Q3 EPS of $3.25, surpassing analyst estimates by $0.39, and revenue of $10.3B, exceeding the consensus of $10.27B. The company also provided strong Q4 2026 guidance for both EPS and revenue, which are above analyst expectations. Despite strong earnings, Salesforce stock has seen a decline in the last 3 and 12 months.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Citizens | $430 | $430 | 0% |
| 2025-12-01 | Oppenheimer | $300 | $315 | -5% |
| 2025-11-26 | Citigroup | $253 | $276 | -8% |
| 2025-11-25 | Cantor Fitzgera | $325 | $325 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Citizens | reit | Market Outperform |
| 2025-12-01 | Oppenheimer | main | Outperform |
| 2025-11-26 | Citigroup | main | Neutral |
| 2025-11-25 | Cantor Fitzgera | reit | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($26.11M) |
| Sells | 37 ($11.66M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.8%)
- Blackrock Inc.: 8.7% (-0.5%)
- State Street Corpora: 5.3% (+0.3%)
- JPMORGAN CHASE & CO: 2.8% (+46.5%)
- Geode Capital Manage: 2.2% (+0.6%)

### Key Risks

1. Heavy insider selling: $12M sold (37 transactions in 90 days).
2. Long-term trend broken: trading 8.2% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.24 suggests fair value with growth premium. Quality metrics strong (margin 18%). Balance sheet: $2.2B free cash flow. Analyst sentiment negative (4 target cuts vs 0 raises). Insider buying signal ($26.1M), management confidence. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $253.3B |
| Beta | 1.25 |
| 52W Range | $221.96 - $367.09 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.24 |
| Forward P/E | 18.2 |
| Current P/E | 20.3 |
| YoY Growth | 11.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.9% to -0.8% (+5.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.0%) - potential reversal signal. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (0.56), confirming momentum. RSI neutral at 50. OFD pattern: +MLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.82% (CS: 43) | Neutral |
| RSI_14 | 50.4 | Neutral |
| MACD Histogram | 0.56 | Bullish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 0.918x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $238.72
- **Stop Loss:** $225.10 (5.7% risk)
- **Target:** $265.96 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 69
- **Position Value:** $16,471.68
- **Portfolio %:** 16.47%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-25 (Est: $3.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.86 | $3.25 | +13.6% |
| 2025Q3 | $2.78 | $2.91 | +4.7% |
| 2025Q2 | $2.55 | $2.58 | +1.3% |
| 2025Q1 | $2.61 | $2.78 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*